

Substitute for form 1449B/PTO

**SIXTH SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
IN AN APPLICATION**
**LISTING OF REFERENCES**
**JUNE 5, 2008**

(Use several sheets if necessary)

**ATTORNEY DOCKET NO.**  
3022.1004-000

**APPLICATION NO.**  
10/088,677

**FIRST NAMED INVENTOR**  
Joerg Schneider

**371(c) DATE**  
May 31, 2002

**EXAMINER**  
Robert A. Zeman

**CONFIRMATION NO.**  
4825

**GROUP**  
1645

**U.S. PATENT DOCUMENTS**

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/RAZ/	A21	6,355,252 B1	03-12-2002	Smith, <i>et al.</i>
/RAZ/	A22	7,273,605	09-25-2007	Laidlaw, <i>et al.</i>
/RAZ/	A23	2001/0036928 A1	11-01-2001	Chamberlain, <i>et al.</i>
/RAZ/	A24	2004/0142002	07-22-2004	Smith, <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/RAZ/	B18	WO 99/41383 A1	08-19-1999	Maxygen, Inc.		
/RAZ/	B19	WO 02/24224 A2	03-28-2002	Oxxon Pharmaccines Limited		
/RAZ/	B20	WO 2005/026370 A2	03-24-2005	Aventis Pasteur Limited and Therion Biologics, Inc.		
/RAZ/	B21	WO 2006/061643 A1	06-15-2006	Oxxon Therapeutics Limited		
/RAZ/	B22	WO 2006/120474 A2	11-16-2006	Oxxon Therapeutics Limited		
/RAZ/	B23	WO 2006/125983 A1	11-30-2006	Oxxon Therapeutics Limited		
/RAZ/	B24	CN 1 324 661 A	12-05-2001	Second Military Medical University, PLA		X

EXAMINER

DATE CONSIDERED

Substitute for form 1449B/PTO  <b>SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>JUNE 5, 2008</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		371(c) DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZ/	C13	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Merck & Co., Inc. [Date signed by Opponent: Feb. 9, 2006 ; Date filed in EPO: Feb. 13, 2006]
/RAZ/	C14	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Crucell Holland B.V. [Date signed by Opponent: Feb. 6, 2006 ; Date filed in EPO: Feb. 13, 2006]
/RAZ/	C15	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416. Opponent: Transgene S.A. (English translation attached.) [Date signed by Opponent: Feb. 3, 2006 ; Date filed in EPO: Feb. 6, 2006]
/RAZ/	C26	The Chamberlain Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]
/RAZ/	C27	The Gritz Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003].
/RAZ/	C28	The Schlom Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Declarant: Sept. 24, 2003; Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]
/RAZ/	C227	Anderson, R., "Treatment of Melanoma by Heterologous PrimeBoost Immunotherapy," Oxxon Therapeutics, TVLN Presentation given on April 6, 2006 (17 pages).
/RAZ/	C228	Chow, Y-H., <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> , 71(1): 169-178 (1997).
/RAZ/	C229	Haigwood, N.L., "Predictive Value of Primate Models for AIDS," <i>AIDS Reviews</i> 6:187-198 (2004).
/RAZ/	C230	Hutchings, C.L., <i>et al.</i> , "Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity," <i>J. Immunol.</i> , 175:599-606 (2005).
/RAZ/	C231	Lindsey, K.R., <i>et al.</i> , "Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 12(8): 2526-2537 (2006).
/RAZ/	C232	Marshall, J.L., <i>et al.</i> , "Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses," <i>J. Clin. Oncol.</i> , 18(23): 3964-3973 (2000).
/RAZ/	C233	Rosenberg, S.A., <i>et al.</i> , Recombinant Fowlpox Viruses Encoding the Anchor-Modified gp100 Melanoma Antigen can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 9(8): 2973-2980 (2003).
/RAZ/	C234	Tagawa, S.T., <i>et al.</i> , "Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma," <i>Cancer</i> , 98(1): 144-154 (2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO  <b>SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>JUNE 5, 2008</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677
	FIRST NAMED INVENTOR Joerg Schneider		371(c) DATE May 31, 2002
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZ/	C235	Tomiyama, H., <i>et al.</i> , "Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Cytolytic Activity and Cytokine Production," <i>J. Virol.</i> , 76(15): 7535-7543 (2002).
/RAZ/	C236	van Baren, N., <i>et al.</i> , "Tumoral and Immunologic Response After Vaccination of Melanoma Patients with an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells," <i>J. Clin. Oncol.</i> , 23(35): 9008-9021(2005).
/RAZ/	C237	Vuola, J.M., <i>et al.</i> , "Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers," <i>J. Immunol.</i> , 174(1): 449-455 (2005).
/RAZ/	C238	Wang, X., <i>et al.</i> , "Cellular Immune Responses to Helper-Free HSV-1 Amplicon Particles Encoding HIV-1 gp120 are Enhanced by DNA Priming," <i>Vaccine</i> , 21(19-20): 2288-2297 (2003).
/RAZ/	C239	Woodberry, T., <i>et al.</i> , "Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection and Th1 Bias," <i>J. Immunol.</i> , 170:2599-2604 (2003).
/RAZ/	C240	Zajac, P., <i>et al.</i> , "Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients," <i>Human Gene Therapy</i> , 14(16): 1497-1510 (2003).

EXAMINER /Robert Zeman/	DATE CONSIDERED 09/25/2008
----------------------------	-------------------------------